Remove Invest Remove Marketing Remove Technology Remove Thousand Oaks
article thumbnail

Teledyne Increases Stake in Robot Maker Ocean Aero

socalTECH

Thousand Oaks-based Teledyne Technologies has increased its stake in San Diego-based Ocean Aero , a developer of unmanned, robotic underwater and surface vehicles used for the scientific, defense, and oil and gas market, the company said late Friday. Teledyne made its initial investment in Ocean Aero in July of 2014.

article thumbnail

Teledyne Buys Majority Stake In Nova Sensors

socalTECH

Thousand Oaks-based Teledyne Technologies said this morning that it has acquired a majority interest in Solvang-based Nova Sensors. Teledyne said the move would bolster its involvement in infrared imaging systems for the commercial and tactical military market. Financial terms of the deal were not disclosed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interview with Brett Crosby and Brew Johnson, PeerStreet

socalTECH

I grew up in Thousand Oaks, went to USC, and we met each other way back in the 90's. We said, let's create a technology marketplace and platform that creates benefits for those existing lenders, as well as investors. So, we're focused on applying technology more efficiently and creating more value for investors.

article thumbnail

Pacific Coast Business Times - Hall of Fame Announced

SoCal Delicious

Home About Us Newsstand locations Special Section Nominations Stock Index Advertising Contact Search Subscribe Weekly Features Week in Review Top 25 Lists Top Stories Local News Opinion Calendar Ongoing Events Monthly Reports Central Coast East Ventura Nonprofits Technology Small Business Women and Co.

article thumbnail

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Xconomy

As a result, Biogen will buy the rights to nusinersen and prepare to ask regulators for marketing approval. Published in January, the technology comes from the lab of Keith Joung, who is an Editas cofounder. SMA has no approved treatments. —Meanwhile, scientists from San Diego-based Synthetic Genomics and the J.

News 40